View ValuationEKF Diagnostics Holdings 향후 성장Future 기준 점검 0/6EKF Diagnostics Holdings의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Medical Equipment 이익 성장16.4%매출 성장률6.0%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트19 May 2026최근 향후 성장 업데이트공시 • Sep 17EKF Diagnostics Holdings plc Provides Earnings Guidance for the Fiscal Year 2025EKF Diagnostics Holdings plc provided earnings guidance for the fiscal year 2025. The company expects to remain on track to deliver growth at the revenue level for the fiscal year 2025 in-line with market expectations of £53.6 million.공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for Full Year 2024EKF Diagnostics Holdings plc provided earnings guidance for full year 2024. For the period, the company expects to report full-year revenues of £50.2 million (FY 2023: £52.6 million), having accelerated the move away from lower margin products.공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023EKF Diagnostics Holdings plc provided earnings guidance for full year 2023. For the period, Company expects revenues in-line with management expectations, reflecting continued steady growth from the Point-of-Care division andß-HB sales.모든 업데이트 보기Recent updates공시 • Apr 29EKF Diagnostics Holdings plc Announces Board Changes, Effective April 27, 2026EKF Diagnostics Holdings plc announced that Helen Jones FCA will join the Board with immediate effect. Helen Jones is an experienced CFO with over 20 years' experience leading finance, operations, and strategic transactions in high-growth, technology-driven AIM listed businesses. Helen joins EKF from Surgical Science, a leading provider of medical simulation solutions, where she has assumed a senior Group-level role following its acquisition of Intelligent Ultrasound Group plc in February 2025, with responsibility spanning post-acquisition integration and operational cost reduction, Group statutory reporting, and sustainability leadership. Prior to the acquisition, Helen spent five years as CFO of Intelligent Ultrasound Group plc, an AIM-listed company supplying simulation and AI-based ultrasound training solutions to the healthcare sector. During her tenure, Helen led two successful equity placings to fund growth and innovation, played a central role in both the £40.6 million divestment of its Clinical AI division to GE Healthcare and the subsequent sale of the Simulation business to Surgical Science. Before joining Intelligent Ultrasound, Helen held a senior finance role within AIM-listed oil and exploration company Amerisur Resources plc and prior to that spent 11 years in various senior financial positions at Tata Steel Europe. Helen is a fellow of the Institute of Chartered Accountants in England and Wales having trained and qualified with PwC in 2004. Helen Mary Kinsey Jones is aged 47. Directorships/partnerships within the last five years: IML Finance Limited, Intelligent Ultrasound Innovations Limited, Intelligent Ultrasound Limited, Intelligent Ultrasound North America Inc, Inventive Medical Limited, Medaphor International Limited, Surgical Science UK Limited, and Surgical Science UK Holdings Limited. Helen succeeds Stephen Young, who is retiring from the Board. Steve will be available to support Helen to ensure a smooth handover but will step down from the Board with immediate effect.공시 • Mar 05EKF Diagnostics Holdings plc to Report Fiscal Year 2025 Results on Mar 24, 2026EKF Diagnostics Holdings plc announced that they will report fiscal year 2025 results on Mar 24, 2026공시 • Feb 20EKF Diagnostics Holdings plc, Annual General Meeting, May 19, 2026EKF Diagnostics Holdings plc, Annual General Meeting, May 19, 2026.공시 • Oct 16EKF Diagnostics Holdings plc (AIM:EKF) commences an Equity Buyback plan for 67,730,993 shares, representing 14.93% of its issued share capital, under the authorization approved on May 20, 2025.EKF Diagnostics Holdings plc (AIM:EKF) commences share repurchases on,October 14, 2025, under the program mandated by the shareholders in the Annual General Meeting held on May 20, 2025. As per the mandate, the company is authorized to repurchase up to 67,730,993 shares, representing 14.93% of its issued share capital. The maximum price which may be paid for an ordinary share is an amount equal to 5% of the average of the middle market quotations for the ordinary shares taken from the London Stock Exchange plc Daily Official List for five business days immediately preceding the day on which that share is contracted to be purchased. The minimum price which may be paid for an ordinary share is £0.01 per share. The repurchased shares will be held as treasury shares for further reissue or to satisfy employee share scheme awards. The authority shall expire at the earliest of the next Annual General Meeting. As of December 31, 2024, the company had 453,730,564 issued shares and 1,200,000 shares in treasury. On May 21, 2025, the company initiated a Market Repurchase. Under the program, the company will repurchase up to £1.0 million worth of its shares.공시 • Sep 17EKF Diagnostics Holdings plc Provides Earnings Guidance for the Fiscal Year 2025EKF Diagnostics Holdings plc provided earnings guidance for the fiscal year 2025. The company expects to remain on track to deliver growth at the revenue level for the fiscal year 2025 in-line with market expectations of £53.6 million.공시 • Jul 28EKF Diagnostics Holdings plc to Report First Half, 2025 Results on Sep 16, 2025EKF Diagnostics Holdings plc announced that they will report first half, 2025 results on Sep 16, 2025공시 • Apr 01EKF Diagnostics Holdings plc (AIM:EKF) commences an Equity Buyback for £0.68 million worth of its shares, under the authorization approved on May 14, 2024.EKF Diagnostics Holdings plc (AIM:EKF) commences share repurchases on March 31, 2025, under the program mandated by the shareholders in the Annual General Meeting held on May 14, 2024. As per the mandate, the company is authorized to repurchase up to for £0.68 million worth of its shares. The repurchased shares will be cancelled or held in treasury. The program will be valid till the next Annual General Meeting.공시 • Mar 26EKF Diagnostics Holdings plc, Annual General Meeting, May 20, 2025EKF Diagnostics Holdings plc, Annual General Meeting, May 20, 2025.공시 • Mar 25+ 1 more updateEKF Diagnostics Holdings plc Appoints Gavin Joseph Jones as Chief Executive OfficerEKF Diagnostics Holdings plc announced the appointment of Gavin Joseph Jones (aged 44) as Chief Executive Officer with immediate effect. Gavin previously served as Chief Product Officer at EKF and has extensive industry experience in Analytical Chemistry and Diagnostics. Julian Baines will remain as Executive Chair for the foreseeable future. In his role as Chief Product Officer, Gavin led the Product Management, R&D, Marketing and Regulatory departments, bringing new and updated products to market, delivering on enhanced connectivity solutions and user-friendly design to meet evolving customer needs. Before joining EKF in 2013, Gavin held a Product Management role at Biotage AB and analyst positions at PCI (then trading as Penn Pharma) and the Forensic Science Service, initially starting out in the laboratory but quickly transitioning to product strategy and innovation. His expertise spans commercial strategy, business development, and product lifecycle management, contributing to significant growth in global healthcare markets. Gavin holds a BSc (Hons) Forensic and Biomolecular Science degree from Liverpool John Moores University and has a track record of driving product innovation and operational excellence. Gavin is committed to expanding EKF's point-of-care solutions and strengthening its market presence in Life Sciences.공시 • Mar 06EKF Diagnostics Holdings plc to Report Fiscal Year 2024 Results on Mar 25, 2025EKF Diagnostics Holdings plc announced that they will report fiscal year 2024 results on Mar 25, 2025공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for Full Year 2024EKF Diagnostics Holdings plc provided earnings guidance for full year 2024. For the period, the company expects to report full-year revenues of £50.2 million (FY 2023: £52.6 million), having accelerated the move away from lower margin products.공시 • Jul 24+ 1 more updateEKF Diagnostics Holdings plc to Report First Half, 2024 Results on Sep 17, 2024EKF Diagnostics Holdings plc announced that they will report first half, 2024 results on Sep 17, 2024공시 • Jul 18EKF Diagnostics Holdings plc Announces the Launch of Its New and Enhanced Biosen C-LineEKF Diagnostics Holdings plc announced the launch of its new and enhanced Biosen C-Line, an industry leading benchtop glucose and lactate analyzer within its Point of Care range, in response to customer demands for greater connectivity options and improved usability. The Biosen C-Line (the "Biosen") is an easy-to-use, POC analyzer which accurately measures glucose and lactate levels in healthcare and sports performance. The Biosen is used by clinical professionals in both primary and secondary care settings around the world to provide fast and accurate glucose analysis for the detection and management of diabetes, a chronic condition which is expected to affect 1.31 billion people worldwide by 2050. The Biosen is also the first choice for elite sports professionals, including international football and Olympic teams, to measure lactate production during training, which provides valuable insights into athletes' metabolic responses during training and competition to help achieve peak performance. The updated Biosen range uses the same proven technology as its predecessor to provide precise and rapid measurements of glucose and lactate levels in whole blood, plasma and serum with just one test. The new version has been enhanced with improved connectivity, and is fully compatible with EKF Link, a middleware solution for healthcare providers to manage their POC analyzers on one centralised platform to enable the real-time remote management of data. EKF Link is a fast and secure method for connecting POC devices to hospital and laboratory IT systems, enabling the safe transfer of data from the analyzer to the hospital or laboratory database for subsequent processing. Integration of technology systems and advanced connectivity is becoming increasingly important to healthcare providers and laboratories around the world, as they look to improve resource utilisation and efficiencies. The addition of EKF Link to the Company's POC portfolio has opened up a number of new tender opportunities around the world, including the Hong Kong and Thai Red Cross partnerships and will continue to aid the Company's growth in the blood bank market globally.공시 • Apr 24EKF Diagnostics Holdings plc, Annual General Meeting, May 14, 2024EKF Diagnostics Holdings plc, Annual General Meeting, May 14, 2024, at 10:00 Coordinated Universal Time. Location: Harwood Capital LLP 6 Stratton Street Mayfair London United Kingdom공시 • Mar 11EKF Diagnostics Holdings plc to Report Fiscal Year 2023 Results on Mar 20, 2024EKF Diagnostics Holdings plc announced that they will report fiscal year 2023 results on Mar 20, 2024공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023EKF Diagnostics Holdings plc provided earnings guidance for full year 2023. For the period, Company expects revenues in-line with management expectations, reflecting continued steady growth from the Point-of-Care division andß-HB sales.공시 • Sep 14EKF Diagnostics Holdings plc to Report Q2, 2023 Results on Sep 26, 2023EKF Diagnostics Holdings plc announced that they will report Q2, 2023 results on Sep 26, 2023공시 • Sep 12+ 1 more updateEKF Diagnostics Holdings plc Appoints Stephen Young as Chief Financial OfficerEKF Diagnostics Holdings plc announced the appointment of Stephen ("Steve") Young as Chief Financial Officer ("CFO") and to the EKF Board, effective immediately. Steve Young has been working as a consultant at EKF for the last two months alongside the Group's outgoing CFO to affect an orderly handover. Steve is an experienced Finance Director and CFO and joins the Company from Trellus Health plc ("Trellus") where he has served as Interim Chief Financial Officer, in a non-board capacity, since August 2022. Prior to working with Trellus, Steve served as CFO and Company Secretary (a non-Director role) with Axiom Manufacturing Limited, a contract electronic manufacturer. Having joined in 2009 when Axiom generated close to £12m in revenue and was loss making, he supported the restructuring of the business to over £62m turnover in 2020. Axiom also acquired Greeve Limited in 2016 where Steve became a Director. In addition to this, Steve has experience with AIM-quoted businesses having served as CFO at Pure Wafer plc and, before this, BBI Holdings plc ("BBI") which admitted to AIM in 2004. During Steve's seven-year tenure at BBI he reported to EKF Executive Chair Julian Baines when he was CEO of BBI. Steve is a member of the Chartered Institute of Management Accountants (CIMA).공시 • Jun 28Marc Davies to Step Down as Chief Financial Officer of EKF Diagnostics Holdings plcEKF Diagnostics Holdings plc announced that Marc Davies is standing down from his role as Chief Financial Officer to pursue other opportunities. Marc will remain in his position to facilitate an orderly handover to his replacement for up to six months, as required. The company is already in advanced discussions with a suitable candidate for the CFO role, who is experienced in working with AIM-quoted healthcare companies, and is be able to commence the handover process within the next few weeks, with a view to taking on the role permanently in Fourth Quarter 2023. A further announcement relating to this appointment will be made in due course. Julian Baines remains Executive Chair and is committed to executing the Company's growth strategy, whilst also overseeing the recruitment process for a new Chief Executive Officer. An experienced senior management team continues to support the Executive Chair on an operational level, alongside significant strategic input from the Non-executive Directors.공시 • Feb 07+ 1 more updateEkf Diagnostics Holdings plc Announces Chair of the Board ChangesEKF Diagnostics Holdings plc announced that Christopher Mills, currently Non-executive Chair will remain a Non-executive Director, and Julian Baines, will assume the role of Executive Chair on a short-term basis, using his skills and experience to best support the Management Team to deliver the required results for the Company. All of the planned EKF Board changes are effective immediately.이익 및 매출 성장 예측OTCPK:EKDH.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202862N/A715312/31/202758N/A614312/31/202655N/A312312/31/2025522710N/A9/30/2025514810N/A6/30/2025506911N/A3/31/20255061012N/A12/31/20245061114N/A9/30/2024516913N/A6/30/2024515612N/A3/31/202452439N/A12/31/2023532-16N/A9/30/202354-5-25N/A6/30/202356-13-34N/A3/31/202361-1117N/A12/31/202267-10410N/A9/30/202274-1714N/A6/30/20228191118N/A3/31/20228112814N/A12/31/20218216510N/A9/30/20218016510N/A6/30/2021771669N/A3/31/20217114911N/A12/31/202065111114N/A9/30/2020589811N/A6/30/202050658N/A3/31/202047546N/A12/31/201945435N/A9/30/2019447N/A7N/A6/30/20194411N/A9N/A3/31/20194310N/A8N/A12/31/20184310N/A8N/A9/30/2018417N/A8N/A6/30/2018404N/A7N/A3/31/2018413N/A8N/A12/31/2017423N/A9N/A9/30/2017422N/A11N/A6/30/2017431N/A13N/A3/31/2017411N/A11N/A12/31/2016390N/A9N/A9/30/201636-11N/A4N/A6/30/201633-22N/A-1N/A3/31/201631-18N/A-3N/A12/31/201530-14N/A-4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: EKDH.F 의 예상 수익 증가율이 절약률(3.5%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: EKDH.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: EKDH.F 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: EKDH.F 의 수익(연간 6%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: EKDH.F 의 수익(연간 6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: EKDH.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 17:18종가2026/05/27 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스EKF Diagnostics Holdings plc는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Julie SimmondsCanaccord GenuityJens LindqvistInvestec Bank plc (UK)Julie SimmondsPanmure Liberum4명의 분석가 더 보기
공시 • Sep 17EKF Diagnostics Holdings plc Provides Earnings Guidance for the Fiscal Year 2025EKF Diagnostics Holdings plc provided earnings guidance for the fiscal year 2025. The company expects to remain on track to deliver growth at the revenue level for the fiscal year 2025 in-line with market expectations of £53.6 million.
공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for Full Year 2024EKF Diagnostics Holdings plc provided earnings guidance for full year 2024. For the period, the company expects to report full-year revenues of £50.2 million (FY 2023: £52.6 million), having accelerated the move away from lower margin products.
공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023EKF Diagnostics Holdings plc provided earnings guidance for full year 2023. For the period, Company expects revenues in-line with management expectations, reflecting continued steady growth from the Point-of-Care division andß-HB sales.
공시 • Apr 29EKF Diagnostics Holdings plc Announces Board Changes, Effective April 27, 2026EKF Diagnostics Holdings plc announced that Helen Jones FCA will join the Board with immediate effect. Helen Jones is an experienced CFO with over 20 years' experience leading finance, operations, and strategic transactions in high-growth, technology-driven AIM listed businesses. Helen joins EKF from Surgical Science, a leading provider of medical simulation solutions, where she has assumed a senior Group-level role following its acquisition of Intelligent Ultrasound Group plc in February 2025, with responsibility spanning post-acquisition integration and operational cost reduction, Group statutory reporting, and sustainability leadership. Prior to the acquisition, Helen spent five years as CFO of Intelligent Ultrasound Group plc, an AIM-listed company supplying simulation and AI-based ultrasound training solutions to the healthcare sector. During her tenure, Helen led two successful equity placings to fund growth and innovation, played a central role in both the £40.6 million divestment of its Clinical AI division to GE Healthcare and the subsequent sale of the Simulation business to Surgical Science. Before joining Intelligent Ultrasound, Helen held a senior finance role within AIM-listed oil and exploration company Amerisur Resources plc and prior to that spent 11 years in various senior financial positions at Tata Steel Europe. Helen is a fellow of the Institute of Chartered Accountants in England and Wales having trained and qualified with PwC in 2004. Helen Mary Kinsey Jones is aged 47. Directorships/partnerships within the last five years: IML Finance Limited, Intelligent Ultrasound Innovations Limited, Intelligent Ultrasound Limited, Intelligent Ultrasound North America Inc, Inventive Medical Limited, Medaphor International Limited, Surgical Science UK Limited, and Surgical Science UK Holdings Limited. Helen succeeds Stephen Young, who is retiring from the Board. Steve will be available to support Helen to ensure a smooth handover but will step down from the Board with immediate effect.
공시 • Mar 05EKF Diagnostics Holdings plc to Report Fiscal Year 2025 Results on Mar 24, 2026EKF Diagnostics Holdings plc announced that they will report fiscal year 2025 results on Mar 24, 2026
공시 • Feb 20EKF Diagnostics Holdings plc, Annual General Meeting, May 19, 2026EKF Diagnostics Holdings plc, Annual General Meeting, May 19, 2026.
공시 • Oct 16EKF Diagnostics Holdings plc (AIM:EKF) commences an Equity Buyback plan for 67,730,993 shares, representing 14.93% of its issued share capital, under the authorization approved on May 20, 2025.EKF Diagnostics Holdings plc (AIM:EKF) commences share repurchases on,October 14, 2025, under the program mandated by the shareholders in the Annual General Meeting held on May 20, 2025. As per the mandate, the company is authorized to repurchase up to 67,730,993 shares, representing 14.93% of its issued share capital. The maximum price which may be paid for an ordinary share is an amount equal to 5% of the average of the middle market quotations for the ordinary shares taken from the London Stock Exchange plc Daily Official List for five business days immediately preceding the day on which that share is contracted to be purchased. The minimum price which may be paid for an ordinary share is £0.01 per share. The repurchased shares will be held as treasury shares for further reissue or to satisfy employee share scheme awards. The authority shall expire at the earliest of the next Annual General Meeting. As of December 31, 2024, the company had 453,730,564 issued shares and 1,200,000 shares in treasury. On May 21, 2025, the company initiated a Market Repurchase. Under the program, the company will repurchase up to £1.0 million worth of its shares.
공시 • Sep 17EKF Diagnostics Holdings plc Provides Earnings Guidance for the Fiscal Year 2025EKF Diagnostics Holdings plc provided earnings guidance for the fiscal year 2025. The company expects to remain on track to deliver growth at the revenue level for the fiscal year 2025 in-line with market expectations of £53.6 million.
공시 • Jul 28EKF Diagnostics Holdings plc to Report First Half, 2025 Results on Sep 16, 2025EKF Diagnostics Holdings plc announced that they will report first half, 2025 results on Sep 16, 2025
공시 • Apr 01EKF Diagnostics Holdings plc (AIM:EKF) commences an Equity Buyback for £0.68 million worth of its shares, under the authorization approved on May 14, 2024.EKF Diagnostics Holdings plc (AIM:EKF) commences share repurchases on March 31, 2025, under the program mandated by the shareholders in the Annual General Meeting held on May 14, 2024. As per the mandate, the company is authorized to repurchase up to for £0.68 million worth of its shares. The repurchased shares will be cancelled or held in treasury. The program will be valid till the next Annual General Meeting.
공시 • Mar 26EKF Diagnostics Holdings plc, Annual General Meeting, May 20, 2025EKF Diagnostics Holdings plc, Annual General Meeting, May 20, 2025.
공시 • Mar 25+ 1 more updateEKF Diagnostics Holdings plc Appoints Gavin Joseph Jones as Chief Executive OfficerEKF Diagnostics Holdings plc announced the appointment of Gavin Joseph Jones (aged 44) as Chief Executive Officer with immediate effect. Gavin previously served as Chief Product Officer at EKF and has extensive industry experience in Analytical Chemistry and Diagnostics. Julian Baines will remain as Executive Chair for the foreseeable future. In his role as Chief Product Officer, Gavin led the Product Management, R&D, Marketing and Regulatory departments, bringing new and updated products to market, delivering on enhanced connectivity solutions and user-friendly design to meet evolving customer needs. Before joining EKF in 2013, Gavin held a Product Management role at Biotage AB and analyst positions at PCI (then trading as Penn Pharma) and the Forensic Science Service, initially starting out in the laboratory but quickly transitioning to product strategy and innovation. His expertise spans commercial strategy, business development, and product lifecycle management, contributing to significant growth in global healthcare markets. Gavin holds a BSc (Hons) Forensic and Biomolecular Science degree from Liverpool John Moores University and has a track record of driving product innovation and operational excellence. Gavin is committed to expanding EKF's point-of-care solutions and strengthening its market presence in Life Sciences.
공시 • Mar 06EKF Diagnostics Holdings plc to Report Fiscal Year 2024 Results on Mar 25, 2025EKF Diagnostics Holdings plc announced that they will report fiscal year 2024 results on Mar 25, 2025
공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for Full Year 2024EKF Diagnostics Holdings plc provided earnings guidance for full year 2024. For the period, the company expects to report full-year revenues of £50.2 million (FY 2023: £52.6 million), having accelerated the move away from lower margin products.
공시 • Jul 24+ 1 more updateEKF Diagnostics Holdings plc to Report First Half, 2024 Results on Sep 17, 2024EKF Diagnostics Holdings plc announced that they will report first half, 2024 results on Sep 17, 2024
공시 • Jul 18EKF Diagnostics Holdings plc Announces the Launch of Its New and Enhanced Biosen C-LineEKF Diagnostics Holdings plc announced the launch of its new and enhanced Biosen C-Line, an industry leading benchtop glucose and lactate analyzer within its Point of Care range, in response to customer demands for greater connectivity options and improved usability. The Biosen C-Line (the "Biosen") is an easy-to-use, POC analyzer which accurately measures glucose and lactate levels in healthcare and sports performance. The Biosen is used by clinical professionals in both primary and secondary care settings around the world to provide fast and accurate glucose analysis for the detection and management of diabetes, a chronic condition which is expected to affect 1.31 billion people worldwide by 2050. The Biosen is also the first choice for elite sports professionals, including international football and Olympic teams, to measure lactate production during training, which provides valuable insights into athletes' metabolic responses during training and competition to help achieve peak performance. The updated Biosen range uses the same proven technology as its predecessor to provide precise and rapid measurements of glucose and lactate levels in whole blood, plasma and serum with just one test. The new version has been enhanced with improved connectivity, and is fully compatible with EKF Link, a middleware solution for healthcare providers to manage their POC analyzers on one centralised platform to enable the real-time remote management of data. EKF Link is a fast and secure method for connecting POC devices to hospital and laboratory IT systems, enabling the safe transfer of data from the analyzer to the hospital or laboratory database for subsequent processing. Integration of technology systems and advanced connectivity is becoming increasingly important to healthcare providers and laboratories around the world, as they look to improve resource utilisation and efficiencies. The addition of EKF Link to the Company's POC portfolio has opened up a number of new tender opportunities around the world, including the Hong Kong and Thai Red Cross partnerships and will continue to aid the Company's growth in the blood bank market globally.
공시 • Apr 24EKF Diagnostics Holdings plc, Annual General Meeting, May 14, 2024EKF Diagnostics Holdings plc, Annual General Meeting, May 14, 2024, at 10:00 Coordinated Universal Time. Location: Harwood Capital LLP 6 Stratton Street Mayfair London United Kingdom
공시 • Mar 11EKF Diagnostics Holdings plc to Report Fiscal Year 2023 Results on Mar 20, 2024EKF Diagnostics Holdings plc announced that they will report fiscal year 2023 results on Mar 20, 2024
공시 • Jan 29EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023EKF Diagnostics Holdings plc provided earnings guidance for full year 2023. For the period, Company expects revenues in-line with management expectations, reflecting continued steady growth from the Point-of-Care division andß-HB sales.
공시 • Sep 14EKF Diagnostics Holdings plc to Report Q2, 2023 Results on Sep 26, 2023EKF Diagnostics Holdings plc announced that they will report Q2, 2023 results on Sep 26, 2023
공시 • Sep 12+ 1 more updateEKF Diagnostics Holdings plc Appoints Stephen Young as Chief Financial OfficerEKF Diagnostics Holdings plc announced the appointment of Stephen ("Steve") Young as Chief Financial Officer ("CFO") and to the EKF Board, effective immediately. Steve Young has been working as a consultant at EKF for the last two months alongside the Group's outgoing CFO to affect an orderly handover. Steve is an experienced Finance Director and CFO and joins the Company from Trellus Health plc ("Trellus") where he has served as Interim Chief Financial Officer, in a non-board capacity, since August 2022. Prior to working with Trellus, Steve served as CFO and Company Secretary (a non-Director role) with Axiom Manufacturing Limited, a contract electronic manufacturer. Having joined in 2009 when Axiom generated close to £12m in revenue and was loss making, he supported the restructuring of the business to over £62m turnover in 2020. Axiom also acquired Greeve Limited in 2016 where Steve became a Director. In addition to this, Steve has experience with AIM-quoted businesses having served as CFO at Pure Wafer plc and, before this, BBI Holdings plc ("BBI") which admitted to AIM in 2004. During Steve's seven-year tenure at BBI he reported to EKF Executive Chair Julian Baines when he was CEO of BBI. Steve is a member of the Chartered Institute of Management Accountants (CIMA).
공시 • Jun 28Marc Davies to Step Down as Chief Financial Officer of EKF Diagnostics Holdings plcEKF Diagnostics Holdings plc announced that Marc Davies is standing down from his role as Chief Financial Officer to pursue other opportunities. Marc will remain in his position to facilitate an orderly handover to his replacement for up to six months, as required. The company is already in advanced discussions with a suitable candidate for the CFO role, who is experienced in working with AIM-quoted healthcare companies, and is be able to commence the handover process within the next few weeks, with a view to taking on the role permanently in Fourth Quarter 2023. A further announcement relating to this appointment will be made in due course. Julian Baines remains Executive Chair and is committed to executing the Company's growth strategy, whilst also overseeing the recruitment process for a new Chief Executive Officer. An experienced senior management team continues to support the Executive Chair on an operational level, alongside significant strategic input from the Non-executive Directors.
공시 • Feb 07+ 1 more updateEkf Diagnostics Holdings plc Announces Chair of the Board ChangesEKF Diagnostics Holdings plc announced that Christopher Mills, currently Non-executive Chair will remain a Non-executive Director, and Julian Baines, will assume the role of Executive Chair on a short-term basis, using his skills and experience to best support the Management Team to deliver the required results for the Company. All of the planned EKF Board changes are effective immediately.